A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.
Fox, Elizabeth
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Dec 2010 - 5174-81 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
1527-7755
10.1200/JCO.2010.30.9674 doi
Administration, Oral
Adolescent
Antineoplastic Agents--administration & dosage
Area Under Curve
Child
Female
Humans
Male
Maximum Tolerated Dose
Neoplasms--drug therapy
Quinazolines--administration & dosage
Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Dec 2010 - 5174-81 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
1527-7755
10.1200/JCO.2010.30.9674 doi
Administration, Oral
Adolescent
Antineoplastic Agents--administration & dosage
Area Under Curve
Child
Female
Humans
Male
Maximum Tolerated Dose
Neoplasms--drug therapy
Quinazolines--administration & dosage
Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors